Skip to main content
. 2019 May 8;11(5):826–836. doi: 10.1080/19420862.2019.1608143

Figure 3.

Figure 3.

Glycan profiles of mAbs with homogeneous glycans. Glycan profiles of commercially available anti-CD20 mAb (a) and glycoengineered G0F mAb (b), G1aF mAb (c), G1bF mAb (d), and G2F mAb (e). The glycan profiles were obtained using HPLC analysis of 2-AB-labeled glycans.